Comparison of 18F-FDG and 68-PSMA-11 in PET for prostate cancer diagnosis
Prostate cancer is the second most incident neoplasm in men, except for non-melanoma skin cancer, and has the second highest mortality rate in Brazil. Early diagnosis increases the chances of cure and enables a less aggressive treatment for the patient. Nuclear Medicine presents effective alternativ...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Brazilian Radiation Protection Society (Sociedade Brasileira de Proteção Radiológica, SBPR)
2022-12-01
|
| Series: | Brazilian Journal of Radiation Sciences |
| Subjects: | |
| Online Access: | https://bjrs.org.br/revista/index.php/REVISTA/article/view/2007 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Prostate cancer is the second most incident neoplasm in men, except for non-melanoma skin cancer, and has the second highest mortality rate in Brazil. Early diagnosis increases the chances of cure and enables a less aggressive treatment for the patient. Nuclear Medicine presents effective alternatives for prostate cancer diagnosis, such as Positron Emission Tomography (PET) or PET and Computed Tomography (PET/CT) imaging. The aim of this study is to compare the advantages and disadvantages of the radiopharmaceuticals 18F-FDG and 68Ga-PSMA-11 used for PET or PET/CT in the diagnosis of this type of cancer. Compared to 18F-FDG, 68Ga-PSMA-11 has some advantages such as its availability by means of generators, the independent production of a cyclotron facility and its theranostic potential. The disadvantages compared to 18F-FDG are the scalability of 18F-FDG production compared to limited generator production. Despite its favorable characteristics, the radiopharmaceutical 18F-FDG has limitations in the diagnosis of some types of tumors, such as prostate cancer. All the favorable and unfavorable aspects of these two radiopharmaceuticals are presented in this work. |
|---|---|
| ISSN: | 2319-0612 |